ATE479678T1 - Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors - Google Patents

Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors

Info

Publication number: ATE479678T1
Authority: AT; Austria
Prior art keywords: pyridines; receptor; benzoimidazole; histamine; modulators
Prior art date: 2006-03-31

Application number

AT07754701T

Other languages

English (en)

Inventor

James Edwards

David Kindrachuk

Jennifer Venable

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-31

Filing date

2007-03-30

Publication date

2010-09-15

2007-03-30 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE479678T1 publication Critical patent/ATE479678T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)

AT07754701T 2006-03-31 2007-03-30 Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors ATE479678T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US78818806P	2006-03-31	2006-03-31
PCT/US2007/008217 WO2007117400A2 (en)	2006-03-31	2007-03-30	Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor

Publications (1)

Publication Number	Publication Date
ATE479678T1 true ATE479678T1 (de)	2010-09-15

Family

ID=38581555

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07754701T ATE479678T1 (de)	2006-03-31	2007-03-30	Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors

Country Status (10)

Country	Link
US (1)	US7589087B2 (de)
EP (1)	EP2004188B1 (de)
JP (1)	JP2009532367A (de)
CN (1)	CN101460168B (de)
AT (1)	ATE479678T1 (de)
AU (1)	AU2007235577B2 (de)
DE (1)	DE602007008859D1 (de)
ES (1)	ES2349237T3 (de)
HK (1)	HK1124767A1 (de)
WO (1)	WO2007117400A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006325294B2 (en) †	2005-10-31	2012-10-11	Merck Sharp & Dohme Corp.	CETP inhibitors
ATE479678T1 (de)	2006-03-31	2010-09-15	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
US7507737B2 (en) *	2006-03-31	2009-03-24	Janssen Pharmaceutica, N.V.	Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor
WO2007120690A2 (en) *	2006-04-10	2007-10-25	Janssen Pharmaceutica N.V.	Combination histamine h1r and h4r antagonist therapy for treating pruritus
US8299028B2 (en)	2007-01-30	2012-10-30	Janssen Pharmaceutica Nv	Chimeric peptide antagonist for GPCR135 or GPCR142
US8084466B2 (en) *	2007-12-18	2011-12-27	Janssen Pharmaceutica Nv	Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
PE20110052A1 (es)	2008-06-12	2011-01-31	Janssen Pharmaceutica Nv	Uso de un antagonista h4 de histamina para el tratamiento de adherencias postoperatorias
US9371311B2 (en)	2008-06-30	2016-06-21	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine derivatives
PL2310012T3 (pl)	2008-06-30	2015-08-31	Janssen Pharmaceutica Nv	Sposób wytwarzania podstawionych pochodnych pirymidyny
AU2013204436B2 (en) *	2008-06-30	2014-12-04	Janssen Pharmaceutica Nv	Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
BRPI0913989A2 (pt)	2008-06-30	2015-10-20	Janssen Pharmaceutica Nv	processo para preparação de derivados de benzoimidazol-2-il pirirmidina
AU2009313400A1 (en) *	2008-11-06	2010-05-14	Musc Foundation For Research Development	Lysosomotropic inhibitors of acid ceramidase
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
WO2011092290A1 (en)	2010-02-01	2011-08-04	Novartis Ag	Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en)	2010-02-02	2014-09-16	Novartis Ag	Cyclohexyl amide derivatives as CRF receptor antagonists
PT2964229T (pt)	2013-03-06	2020-03-23	Janssen Pharmaceutica Nv	Moduladores de piridina benzimidazol-2-ilo do recetor h4 de histamina

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2277273C (en)	1997-01-17	2008-03-25	Merck & Co., Inc.	Integrin antagonists
WO1999018079A1 (en)	1997-10-06	1999-04-15	Warner-Lambert Company	Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
CN1312807A (zh)	1998-06-19	2001-09-12	希龙公司	糖元合成酶激酶3的抑制剂
IL147184A0 (en)	1999-06-23	2002-08-14	Aventis Pharma Gmbh	Substituted benzimidazole
ID30204A (id)	1999-12-27	2001-11-15	Japan Tobacco Inc	Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
EP1296977A1 (de)	2000-06-23	2003-04-02	Bristol-Myers Squibb Pharma Company	Heteroaryl-phenyl-substituierte factor xa inhibitoren
EP1317433A2 (de)	2000-09-06	2003-06-11	Chiron Corporation	Inhibitoren von glycogen synthase kinase 3
EP1370250A2 (de)	2001-03-23	2003-12-17	Chugai Seiyaku Kabushiki Kaisha	Flt-1 liganden sowie deren verwendung zur behandlung von durch angiogenese regulierbaren erkrankungen
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US7314937B2 (en) *	2002-03-21	2008-01-01	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
DE60326735D1 (de)	2002-08-02	2009-04-30	Genesoft Pharmaceuticals Inc	Biaryl-verbindungen mit antiinfektiver wirkung
CA2497829A1 (en) *	2002-09-06	2004-03-18	Janssen Pharmaceutica, N.V.	Method to treat allergic rhinitis
TW200501960A (en)	2002-10-02	2005-01-16	Bristol Myers Squibb Co	Synergistic kits and compositions for treating cancer
EP1653970A4 (de)	2003-08-13	2008-10-15	Novartis Vaccines & Diagnostic	Gsk-3 hemmer und ihre verwendungen
BRPI0414581C1 (pt) *	2003-09-22	2021-05-25	Mei Pharma Inc	composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
DE602004020364D1 (de) *	2003-09-30	2009-05-14	Janssen Pharmaceutica Nv	Benzoimidazolverbindungen
US7115646B2 (en)	2003-10-08	2006-10-03	Bristol Myers Squibb, Co.	Cyclic diamines and derivatives as factor Xa inhibitors
BR0318576A (pt) *	2003-11-11	2006-10-10	Wockhardt Ltd	processo para a fabricação de 1,2-benzisoxazol-3-metanossulfonamida
MXPA06011021A (es) *	2004-03-25	2007-04-13	Johnson & Johnson	Compuestos de imidazol.
EP1824832B1 (de) *	2004-06-30	2011-04-27	Janssen Pharmaceutica NV	Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
WO2006042102A2 (en) *	2004-10-05	2006-04-20	Neurogen Corporation	Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
WO2006102645A1 (en)	2005-03-24	2006-09-28	Janssen Pharmaceutica, N.V.	Biaryl derived amide modulators of vanilloid vr1 receptor
AU2006325294B2 (en)	2005-10-31	2012-10-11	Merck Sharp & Dohme Corp.	CETP inhibitors
US7507737B2 (en)	2006-03-31	2009-03-24	Janssen Pharmaceutica, N.V.	Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor
ATE479678T1 (de)	2006-03-31	2010-09-15	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
WO2007120690A2 (en)	2006-04-10	2007-10-25	Janssen Pharmaceutica N.V.	Combination histamine h1r and h4r antagonist therapy for treating pruritus

2007
- 2007-03-30 AT AT07754701T patent/ATE479678T1/de not_active IP Right Cessation
- 2007-03-30 DE DE602007008859T patent/DE602007008859D1/de active Active
- 2007-03-30 JP JP2009503075A patent/JP2009532367A/ja active Pending
- 2007-03-30 WO PCT/US2007/008217 patent/WO2007117400A2/en active Application Filing
- 2007-03-30 US US11/731,048 patent/US7589087B2/en active Active
- 2007-03-30 CN CN2007800202694A patent/CN101460168B/zh not_active Expired - Fee Related
- 2007-03-30 ES ES07754701T patent/ES2349237T3/es active Active
- 2007-03-30 AU AU2007235577A patent/AU2007235577B2/en not_active Ceased
- 2007-03-30 EP EP07754701A patent/EP2004188B1/de active Active
2009
- 2009-03-09 HK HK09102248.7A patent/HK1124767A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2007235577B2 (en)	2011-09-15
WO2007117400A2 (en)	2007-10-18
AU2007235577A1 (en)	2007-10-18
EP2004188A4 (de)	2009-04-22
US7589087B2 (en)	2009-09-15
DE602007008859D1 (de)	2010-10-14
CN101460168A (zh)	2009-06-17
EP2004188B1 (de)	2010-09-01
ES2349237T3 (es)	2010-12-29
WO2007117400A3 (en)	2008-02-21
EP2004188A2 (de)	2008-12-24
US20070232616A1 (en)	2007-10-04
HK1124767A1 (en)	2009-07-24
JP2009532367A (ja)	2009-09-10
CN101460168B (zh)	2013-07-17

Publication	Publication Date	Title
ATE479678T1 (de)	2010-09-15	Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
UA95949C2 (ru)	2011-09-26	Бензоимидазол-2-илпиримидины и пиразины как модуляторы рецептора гистамина h4
MY145349A (en)	2012-01-31	Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
MX2009008787A (es)	2010-02-15	Moduladores 2-aminopirimidina del receptor de histamina h4.
MY158927A (en)	2016-11-30	Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
MA32975B1 (fr)	2012-01-02	Antagonistes de c5ar
ATE445624T1 (de)	2009-10-15	Verbindungen und zusammensetzungen als ppar- modulatoren
DE602008002733D1 (de)	2010-11-04	Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
ATE469895T1 (de)	2010-06-15	Cgrp-rezeptorantagonisten
ATE478072T1 (de)	2010-09-15	Spiroimidazol-derivate als ppar-modulatoren
WO2007117401A3 (en)	2008-06-26	Indoles and benzoimidazoles as modulators of the histamine h4 receptor
ATE483685T1 (de)	2010-10-15	1-benzensulfonyl-1h-indol-derivate als hemmer der ccr9-aktivität
DE602007010764D1 (en)	2011-01-05	Benzamidglucokinaseaktivatoren
NO20084007L (no)	2008-10-07	Spirokondenserte piperidiner som modulatorer av muskarinreseptorer
CA2903737C (en)	2021-05-18	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
WO2007115192A3 (en)	2007-12-21	P2x7 antagonists to treat affective disorders
JO2694B1 (en)	2013-03-03	Pyramidines Benzo Imidazole-2-IL and Pyrazinate as histamine H4 receptor regulators
MX2012003603A (es)	2012-04-20	Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihid ropiridina fluoro-sustituidos y procedimientos de uso de los mismos.
UA106046C2 (uk)	2014-07-25	Діамінопіридинові, піримідинові і піридазинові модулятори гістамінового рецептора h4
DE502006008280D1 (de)	2010-12-23	Imino-oxazolidine und ihre verwendung als antikoagulantien
TW200609234A (en)	2006-03-16	Heterocyclic compounds
WO2008057543A3 (en)	2009-04-09	Uii-modulating compounds and their use

Legal Events

Date	Code	Title	Description
2011-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties